Atara Biotherapeutics, Inc. develops cell-based immunotherapies using its Epstein-Barr virus (EBV) T-cell platform. The company focuses on allogeneic (donor-derived) T cells and next-generation CAR T technologies to target and eliminate disease-causing cells. Atara's products aim to address cancer and autoimmune diseases, serving patients globally through its advanced manufacturing capabilities.
